 |
|
|
|
 |
|
|
| Article 1 to 10 out of 27 concerning deCODE genetics
|
-
A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence
(04/09/2008)
Cigarette smoking is a major public health problem that contributes to millions of deaths around the world each year. While the health risks of smoking are well known, relatively little is known about why some people are particularly likely to get ...
-
deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
(02/04/2008)
Scientists from deCODE genetics report the discovery of two common, single-letter variants in the sequence of the human genome (SNPs) that regulate one of the principle motors of evolution. Versions of the two SNPs, located on chromosome 4p16, have ...
-
Not only lipids and inflammation: Insight into a new cause of heart attack and other vascular disease
(01/08/2008)
deCODE scientists report that the genetic variant on chromosome 9p21 that the company has linked to increased risk of heart attack is also associated with up to 70% increase in risk of abdominal aortic aneurysm (AAA) and intracranial aneurysm (IA). ...
-
deCODE Gene Discovery Points to New Approach for Treating Major Sleep Disorder
(07/20/2007)
Scientists at deCODE genetics in collaboration with colleagues from Emory University report the discovery of the first variant in the sequence of the human genome ever linked to risk of Restless Legs Syndrome (RLS) and Periodic Limb Movements ...
-
deCODE Announces Appointment of Peter Goodfellow to Board of Directors
(09/15/2006)
deCODE genetics announced that it has named Dr. Peter Goodfellow to its Board of Directors, effective immediately.Dr. Goodfellow was until recently Senior Vice President for Discovery Research at GlaxoSmithKline, a position he held for the past six ...
-
deCODE Study Links Gene Variant to Risk of Breast Cancer
(06/22/2006)
A population-based study by a team of deCODE scientists and colleagues at Iceland's National University Hospital provides a detailed look at the impact of a gene variant on risk of breast cancer. The variant is within a gene called BARD1 ...
-
deCODE Initiates Phase III Trial for DG031 for the Prevention of Heart Attack
(05/19/2006)
Pioneering use of human genetics to target the causative biology
deCODE genetics announced the initiation of patient enrollment in the pivotal Phase III trial for DG031, deCODE's lead developmental compound for the prevention of heart attack.The multicenter Phase III trial will be randomized, double-blind, ...
-
deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics
(05/17/2006)
Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer
deCODE genetics and Illumina, Inc. announced the formation of a strategic alliance under which the companies plan to co-develop and commercialize DNA-based diagnostic tests in several major disease areas. The alliance will employ Illumina's platform ...
-
deCODE Successfully Completes Phase I Clinical Program for DG041 for the Treatment of Peripheral Artery Disease
(02/24/2006)
deCODE genetics announced top-line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD). The company has completed the Phase I studies of DG041 and expects to begin ...
-
deCODE Expands Cancer Program through Acquisition of Icelandic Cancer Research Group
(01/20/2006)
deCODE genetics announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS). The acquisition enables deCODE to broaden and enhance its cancer program by applying the company's unique gene discovery and drug ...
Additional information
deCODE genetics
Reykjavik, Iceland
Company
|
|
|
|
|
|
Top
